Oprymea (Pramipexole)

Pramipexole, the active ingredient in Oprymea, is a dopamine agonist presented as a oral tablet for oral use. It is used to treat symptoms of Parkinson's disease and Restless Legs Syndrome in adults. GNH USA supplies Oprymea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oprymea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pramipexole is indicated for dopaminergic therapy in movement‑disorder pathways. - Parkinson's disease: Improves motor symptoms such as tremor, rigidity and bradykinesia. - Restless Legs Syndrome (RLS): Reduces the urge to move the legs and associated discomfort. - Secondary Parkinsonism: Helps manage motor deficits when Parkinson‑like symptoms arise from other causes. - Prolact  t